Filing Details

Accession Number:
0001104659-23-001945
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-06 20:00:30
Reporting Period:
2023-01-04
Accepted Time:
2023-01-06 20:00:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1720893 Bioxcel Therapeutics Inc. BTAI Pharmaceutical Preparations (2834) 821386754
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1733387 Krishnan Nandabalan C/O Bioxcel Therapeutics, Inc.,
555 Long Wharf Drive
New Haven CT 06511
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-04 34,111 $0.41 34,111 No 4 M Direct
Common Stock Disposition 2023-01-04 24,290 $21.59 9,821 No 4 S Direct
Common Stock Disposition 2023-01-04 9,821 $22.21 0 No 4 S Direct
Common Stock Acquisiton 2023-01-05 25,889 $0.41 25,889 No 4 M Direct
Common Stock Disposition 2023-01-05 25,089 $22.32 800 No 4 S Direct
Common Stock Disposition 2023-01-05 800 $22.93 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Disposition 2023-01-04 34,111 $0.00 34,111 $0.41
Common Stock Stock Options Disposition 2023-01-05 25,889 $0.00 25,889 $0.41
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
379,889 2027-08-23 No 4 M Direct
354,000 2027-08-23 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 8,546,750 Indirect See footnote
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1.
  2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.03 to $22.0263. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  3. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.0367 to $22.42. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  4. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $21.90 to $22.89. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  5. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $22.90 to $23.04. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
  6. These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is a manager and officer of BioXcel LLC and is a director, officer and stockholder of Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
  7. The options are fully vested and exercisable.